“Mounjaro® KwikPen™ 15 mg is the maximum approved dose of tirzepatide, offering the most potent clinical effects on blood glucose regulation and body weight reduction. It is prescribed for patients who have tolerated lower doses well but require maximum therapeutic benefit.

At this strength, tirzepatide delivers powerful appetite suppression, improved insulin sensitivity, and sustained glycemic stability. It is particularly beneficial for patients with long-standing type 2 diabetes and obesity who need aggressive metabolic control.

Despite its high potency, the once-weekly dosing schedule and pre-filled KwikPen design ensure ease of use and treatment compliance.”